CD80 and neoplasm: Moreover, PD-1 signaling was recently proposed to affect antigen-presenting cells more than tumor cells owing to the increased CD80/CD86 expression on antigen-presenting cells, given that the CD28 receptor is the primary target for PD-1/SHP2-mediated dephosphorylation, as was newly discovered in that study (84).